Corbus posts first US data on challenger to Pfizer’s ADC Padcev

CAR-T Digest - August 2020

19 Feb 2025: Corbus posts first US data on challenger to Pfizer’s ADC Padcev

Corbus Pharmaceuticals’ western trial of its ADC showed a 27% response rate, aligning with prior Chinese data
The ADC, licensed from CSPC Pharmaceutical, aims to rival Pfizer’s Padcev, with potential advantages in efficacy and dosing
The trial included diverse tumor types, showing promise in head and neck cancer, where it outperformed Padcev’s response rate
Safety data suggests fewer cases of peripheral neuropathy and skin toxicity compared to Padcev, with mitigated eye reaction risks
Corbus is optimizing the ADC dose, banking on its longer half-life and lower drug-antibody ratio for improved treatment outcomes